Palavras-chave
Como Citar
Resumo
A microbiota intestinal, uma comunidade complexa de microrganismos, tem emergido como modulador crucial na homeostase do hospedeiro e na resposta a doenças como o melanoma, um câncer de pele altamente agressivo. Este artigo revisa os mecanismos pelos quais a microbiota influencia o desenvolvimento, progressão e resposta terapêutica do melanoma. A interação entre a microbiota e o sistema imunológico é analisada, mostrando como os microrganismos comensais modulam a resposta imune inata e adaptativa por meio da interação com células dendríticas, macrófagos, linfócitos T, e da produção de citocinas e quimiocinas. Também se discute o impacto de metabólitos microbianos, como ácidos graxos de cadeia curta, ácidos biliares secundários e compostos fenólicos derivados da dieta, na sinalização celular e modulação do microambiente tumoral. Estrategias emergentes, como o uso de probióticos, prebióticos, antibióticos seletivos, transplante de microbiota fecal e intervenções dietéticas, são avaliadas pelo seu potencial em otimizar a resposta terapêutica e mitigar efeitos adversos. A integração de abordagens baseadas na modulação microbiana pode transformar o tratamento do melanoma, melhorando a eficácia terapêutica e a qualidade de vida dos pacientes. Futuras pesquisas devem focar na personalização dessas intervenções, considerando a composição microbiana individual dos pacientes e os mecanismos subjacentes a essas interações.
Referências
ALVES COSTA SILVA, Carolina et al. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial. Nature Communications, v. 15, n. 1, p. 1633, 2024.
ANGRISH, Manish D.; AGHA, Arun; PEZO, Rossanna C. Association of antibiotics and other drugs with clinical outcomes in metastatic melanoma patients treated with immunotherapy. Journal of Skin Cancer, v. 2021, n. 1, p. 9120162, 2021.
CHEN, Luping et al. Interactions between toll‐like receptors signaling pathway and gut microbiota in host homeostasis. Immunity, Inflammation and Disease, v. 12, n. 7, p. e1356, 2024.
CHEN, Wenbo et al. Bile acids promote the development of HCC by activating the inflammasome. Hepatology Communications, v. 7, n. 9, p. e0217, 2023.
CIERNIKOVA, Sona et al. Microbiome in Cancer Development and Treatment. Microorganisms, v. 12, n. 1, p. 24, 2023.
CORRALES, Eyleen et al. PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma. Cell Communication and Signaling, v. 20, n. 1, p. 187, 2022.
DAVAR, Diwakar et al. Randomized phase II trial of pembrolizumab/lenvatinib (P+ L)+/-responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL). 2024.
DI LUCCIA, Blanda et al. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti–PD-1 tumor immunotherapy. Science immunology, v. 9, n. 95, p. eadi5374, 2024.
FELCHLE, H. et al. Influence of Bacterial Metabolites on the Systemic Antitumor Immune Response after Radiation Therapy in Combination with Immune Checkpoint Inhibitors. International Journal of Radiation Oncology, Biology, Physics, v. 117, n. 2, p. e229, 2023.
GLITZA, Isabella C. et al. Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity. Cancer Discovery, v. 14, n. 7, p. 1161-1175, 2024.
GUTIERREZ-MARTINEZ, Veronica Dayali et al. Uncovering a novel mechanism: Butyrate induces estrogen receptor alpha activation independent of estrogen stimulation in MCF-7 breast cancer cells. Genetics and Molecular Biology, v. 47, n. 1, p. e20230110, 2024.
JEONG, Yoon et al. Microbial β-Glucuronidase Hydrogel Beads Activate Chemotherapeutic Prodrug. ACS Applied Materials & Interfaces, 2024.
JIA, Zhenhua et al. The mechanism of sodium butyrate on the growth of mouse B16 melanoma cells by inhibiting the differentiation of M2-type macrophages and down-regulating the expressions of VEGF and TGF-β. Biotechnology and Genetic Engineering Reviews, p. 1-11, 2023.
JI, Guofeng et al. Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria. Advanced Drug Delivery Reviews, p. 115345, 2024.
JIMINEZ, Victoria; YUSUF, Nabiha. Role of the Microbiome in Immunotherapy of Melanoma. The Cancer Journal, v. 29, n. 2, p. 70-74, 2023.
LAU, Harry Cheuk Hay; ZHANG, Xiang; YU, Jun. Gut microbiota and immune alteration in cancer development: implication for immunotherapy. eGastroenterology, v. 1, n. 1, 2023.
LIN, Xing et al. Hsa_circ_0103232 promotes melanoma cells proliferation and invasion via targeting miR-661/RAB3D. Cell Cycle, v. 21, n. 17, p. 1811-1826, 2022.
LIU, Xia; HOFT, Daniel F.; PENG, Guangyong. Tumor microenvironment metabolites directing T cell differentiation and function. Trends in immunology, v. 43, n. 2, p. 132-147, 2022.
LO, Emily Kwun Kwan et al. Gut microbiota: Impact on 5-fluorouracil efficacy and toxicity. Current Opinion in Toxicology, p. 100423, 2023.
PAL, Subhashis et al. The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cell homing to bone. The Journal of Clinical Investigation, v. 132, n. 12, 2022.
MAARSE, Boukje C. Eveleens et al. Impact of fibre supplementation on microbiome and resilience in healthy participants: A randomized, placebo-controlled clinical trial. Nutrition, Metabolism and Cardiovascular Diseases, v. 34, n. 6, p. 1416-1426, 2024.
MAKARANKA, Stanislau et al. The gut microbiome and melanoma: A review. Experimental Dermatology, v. 31, n. 9, p. 1292-1301, 2022.
MARTINELLI, Serena et al. Synergistic strategies for gastrointestinal cancer care: unveiling the benefits of immunonutrition and microbiota modulation. Nutrients, v. 15, n. 20, p. 4408, 2023.
NATARELLI, Nicole et al. The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients. Journal of Drugs in Dermatology: JDD, v. 23, n. 2, p. 78-84, 2024.
PEI, Bo et al. Bifidobacterium modulation of tumor immunotherapy and its mechanism. Cancer Immunology, Immunotherapy, v. 73, n. 5, p. 94, 2024.
POURHANIFEH, Mohamad H. et al. Resveratrol: a new potential therapeutic agent for melanoma?. Current medicinal chemistry, v. 28, n. 4, p. 687-711, 2021.
ROUTY, Bertrand et al. Melanoma and microbiota: Current understanding and future directions. Cancer cell, v. 42, n. 1, p. 16-34, 2024.
ROWAIYE, Adekunle et al. Gut microbiota alteration-cancer relationships and synbiotic roles in cancer therapies. The Microbe, p. 100096, 2024.
SAITO, Suguru et al. Probiotic lactic acid bacteria promote anti-tumor immunity through enhanced major histocompatibility complex class I-restricted antigen presentation machinery in dendritic cells. Frontiers in Immunology, v. 15, p. 1335975, 2024.
SHEN, Alan et al. Germline variant positive melanoma patients exhibit an enhanced inflammatory microenvironment. Cancer Research, v. 83, n. 7_Supplement, p. 5963-5963, 2023.
SIPOS, Dávid et al. Encapsulation protocol for fecal microbiota transplantation. Frontiers in Cellular and Infection Microbiology, v. 14, p. 1424376, 2024.
SONG, Panwei; PENG, Zhi; GUO, Xiaohuan. Gut microbial metabolites in cancer therapy. Trends in Endocrinology & Metabolism, 2024.
SZÓSTAK, Natalia et al. Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy. Cancer Immunology Research, v. 12, n. 4, p. 427-439, 2024.
TANG, Xiaoyu et al. Tumor microbiota affects the efficacy of tea polyphenols therapy in breast tumor. Food Bioscience, p. 104500, 2024.
TRIPODI, Lorella et al. Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma. IScience, v. 26, n. 10, 2023.
VAMBHURKAR, Ganesh et al. Quality by Design Galvanized development of resveratrol loaded PLGA nanoparticles: In vitro and Ex vivo evaluation for the non-invasive treatment of metastatic melanoma. Journal of Drug Delivery Science and Technology, v. 91, p. 105252, 2024.
VAN HENSBERGEN, Vincent P.; HU, Xiaoyu. Pattern recognition receptors and the innate immune network. In: Molecular Medical Microbiology. Academic Press, 2024. p. 407-441.
XIA, Liliang et al. The Gut Microbiota Improves the Efficacy of Immune-checkpoint Inhibitor Immunotherapy against Tumors: from Association to Cause and Effect. Cancer Letters, p. 217123, 2024.
ZEB, Falak et al. Molecular crosstalk between polyphenols and gut microbiota in cancer prevention. Nutrition Research, v. 124, p. 21-42, 2024.
WANG, Man et al. The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes. Frontiers in Immunology, v. 13, p. 1096551, 2023.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Tuany Caroline Bernardi, Vanessa Mazzardo , Isabele Dallacort, Ana Maria Miyawaki Paulino, Maria Eduarda Madalozzo, Bernardo Augusto Barancelli, Aline Reinert Dazzi , Daniel Hummig , Natally Gabrielly Martin Fernandes, Flávia Teston Furlan , Bruna Luana Chapla , Matheus Henrique Vilani, Tulio Tozzi Fedrigo